LEADER 05531nam 2200685 450 001 9910459699603321 005 20200520144314.0 010 $a1-118-90141-X 010 $a1-118-90138-X 035 $a(CKB)3710000000361281 035 $a(EBL)1895726 035 $a(SSID)ssj0001438522 035 $a(PQKBManifestationID)11916980 035 $a(PQKBTitleCode)TC0001438522 035 $a(PQKBWorkID)11377128 035 $a(PQKB)10697108 035 $a(MiAaPQ)EBC1895726 035 $a(PPN)189834587 035 $a(Au-PeEL)EBL1895726 035 $a(CaPaEBR)ebr11027518 035 $a(CaONFJC)MIL770056 035 $a(OCoLC)881518557 035 $a(EXLCZ)993710000000361281 100 $a20150312h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aPharmaceutical amorphous solid dispersions /$fedited by Ann Newman, Seventh Street Development Group Lafayette, Indiana, USA ; contributors, Patrick Augustijns [and forty seven others] 210 1$aHoboken, New Jersey :$cWiley,$d2015. 210 4$dİ2015 215 $a1 online resource (1218 p.) 300 $aDescription based upon print version of record. 311 $a1-118-45520-7 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCover; Title Page; Copyright; Dedication; Preface; Contributors; 1.1 Introduction; 1.2 Formation of the Amorphous State and the Glass Transition Temperature; 1.3 Structure of Amorphous Solids; 1.4 Molecular Mobility in Amorphous Solids; 1.5 Solid-State Crystallization from the Amorphous State; 1.6 Supersaturation of API in Aqueous Media from the Amorphous State; 1.7 Mixtures of Amorphous Solids; 1.8 Formation and Properties of Amorphous Solid Dispersions; 1.9 Solid-State Crystallization from Amorphous Dispersions; 1.10 Dissolution and Supersaturation of API from Amorphous Solid Dispersions 327 $a1.11 Pharmaceutical Development of Amorphous Solid DispersionsReferences; Chapter 1: Introduction to Amorphous Solid Dispersions; 2.1 Polymers Commonly Used in Amorphous Solid Dispersions; 2.2 Surfactants Commonly Used in Solid Dispersions; 2.3 Synergies between Surfactants and Polymers in Solid Dispersion Systems; 2.4 Physical Properties of Materials and Considerations in Designing Solid Dispersions; References; Chapter 2: Polymers and Surfactants; 3.1 Introduction; 3.2 Amorphous Dispersion Screening; 3.3 Amorphous Solid Dispersion Selection; 3.4 Case Study; 3.5 Conclusions; References 327 $aChapter 3: Amorphous Solid Dispersion Screening4.1 Introduction; 4.2 Thermal Analysis Methods; 4.3 Dielectric Relaxation Methods; 4.4 Moisture Sorption Methods; 4.5 Vibrational Spectroscopy and Microspectroscopy; 4.6 Solid-State NMR Spectroscopy; 4.7 Other Molecular Spectroscopic Methods; 4.8 X-Ray Diffractometry; 4.9 Microscopic and Surface Analysis Methods; 4.10 Other Emerging Analytical Methods; 4.11 Computational Models; 4.12 Conclusions; Acknowledgments; References; Chapter 4: Solid-State Characterization of Amorphous Dispersions; 5.1 Introduction 327 $a5.2 Theory of Crystallization in the Solid State5.3 Factors Impacting the Crystallization Tendency of Active Pharmaceutical Compounds; 5.4 Role of Additives in Modifying Solid-State Crystallization; 5.5 Assessment of Physical Stability; 5.6 Crystallization in Aqueous Environments; 5.7 Summary and Outlook; References; Chapter 5: Physical Stability and Crystallization Inhibition; 6.1 Solubility and Dissolution: An Overview; 6.2 Differences Between Crystalline API, Amorphous Materials, and Amorphous Dispersions as it Pertains to Solubility and Dissolution 327 $a6.3 The Relationship of Polymer Properties with Solubility, Dissolution, and Supersaturation6.4 Solubility and Dissolution Factors to Consider for Dispersions; 6.5 Solubility and Dissolution Measurements for Amorphous Dispersions: Summary, Conclusions, and Recommendations; Acknowledgments; References; Chapter 6: Solubility and Dissolution Considerations for Amorphous Solid Dispersions; 7.1 Introduction: Translational Drug Development; 7.2 Translational Development at the Discovery Stage; 7.3 Translational Development After Discovery; 7.4 Conclusions; References 327 $aChapter 7: Translational Development of Amorphous Dispersions 330 $aProviding a roadmap from early to late stages of drug development, this book overviews amorphous solid dispersion technology - a leading platform to deliver poorly water soluble drugs, a major hurdle in today's pharmaceutical industry. Helps readers understand amorphous solid dispersions and apply techniques to particular pharmaceutical systems Covers physical and chemical properties, screening, scale-up, formulation, drug product manufacture, intellectual property, and regulatory considerations Has an appendix with structure and property information for polymers commonly used in drug developm 606 $aPharmaceutical technology 606 $aAbsorption 606 $aSolubility 608 $aElectronic books. 615 0$aPharmaceutical technology. 615 0$aAbsorption. 615 0$aSolubility. 676 $a615.7 702 $aNewman$b Ann$c(Pharmaceutical scientist), 702 $aAugustijns$b Patrick 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910459699603321 996 $aPharmaceutical amorphous solid dispersions$92023596 997 $aUNINA